NewcelX (NCEL) Current Deferred Revenue (2022 - 2025)

NewcelX (NCEL) posted quarterly Current Deferred Revenue of $1.7 million for Q4 2025, down 33.04% quarter-over-quarter from $2.5 million in Q2 2024.

NewcelX (NCEL) Current Deferred Revenue (2022 - 2025) Analysis & Trends

NewcelX (NCEL) has reported Current Deferred Revenue for 4 consecutive years, with $1.7 million the latest figure, recorded in Q4 2025.

In Q4 2025, Current Deferred Revenue changed N/A year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.7 million (changed N/A YoY), while the FY2025 annual figure was $1.7 million, changed N/A from the prior year.
Current Deferred Revenue eased to $1.7 million in Q4 2025 per NCEL's latest filing, from $2.5 million in the prior quarter.
Across five years, Current Deferred Revenue topped out at $2.5 million in Q4 2022 and bottomed at $1.7 million in Q4 2025.
Historically, Current Deferred Revenue has averaged $2.3 million across 4 years, with a median of $2.5 million in 2023.
On a YoY basis, Current Deferred Revenue climbed as much as 0.0% in 2023 and fell as far as 0.0% in 2023.
NewcelX's Current Deferred Revenue stood at $2.5 million in 2022, then slipped by 0.0% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then slumped by 33.04% to $1.7 million in 2025.
Business Quant data shows NCEL's Current Deferred Revenue at $1.7 million in Q4 2025, $2.5 million in Q2 2024, and $2.5 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.60 Bn	130.75 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.93 Bn	77.93 Bn	3.93 Bn
3	Argenx Se	65.06 Bn	59.88 Bn	1.37 Bn
4	Moderna	56.22 Bn	51.08 Bn	52.00 Mn
5	BeOne Medicines	42.03 Bn	36.93 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.65 Bn	28.34 Bn	992.69 Mn
7	BioNTech SE	27.70 Bn	9.31 Bn	668.28 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.48 Bn	-
10	NewcelX	12.54 Mn	10.34 Mn	-

Download Data